[Treatment of paroxysmal supraventricular tachycardia and tachyarrhythmia with verapamil].
The antiarrhythmic effect of isoptin was verified in 47 patients--30 with paroxysmal supraventricular tachycardia and 17--with paroxysmal ventricular fibrillation: in case of paroxysmal supraventricular tachycardia with 5--10 mg isoptin i.v. for the restoration of sinus rhythm and with 240--320 mg orally for maintaining the effect and in case of ventricular fibrillation--i. v. for the slowing down the heart rate. Isoptin, i. v. applied, restores the sinus rhythm in 93,3 per cent of the patients with paroxysmal supraventricular tachycardia and in 17,6 per cent--with ventricular fibrillation and slowsdown the heart rate in 94,6 per cent among those with ventricular fibrillation. The oral isoptin reduces the paroxysms of the supraventricular tachycardia in 86 per cent and slowsdown the sinus rate and lengthens PQ.
D000328:Adult; D000368:Aged; D001281:Atrial Fibrillation / Q000188:drug therapy* / Q000503:physiopathology; D001794:Blood Pressure / Q000187:drug effects; D004341:Drug Evaluation; D005260:Female; D006339:Heart Rate / Q000187:drug effects; D006801:Humans; D008297:Male; D008875:Middle Aged; D011674:Pulse / Q000187:drug effects; D013614:Tachycardia, Paroxysmal / Q000188:drug therapy* / Q000503:physiopathology; D014700:Verapamil / Q000627:therapeutic use*
D014700:Verapamil
Lechenie na paroksizmalnite supraventrikularni takhikardii i takhiaritmii s verpamil.